NASDAQ : ZYME
Zymeworks Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 28.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.04B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.06B |
| Enterprise Value | 1.75B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 70.96M |
| Shares Outstanding | 70.96M |
| Shares Change (YoY) | -0.84% |
| Shares Change (QoQ) | -2.28% |
| Owned by Insiders (%) | 1.34% |
| Owned by Institutions (%) | 45.42% |
| Float | 65.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 14.28 |
| PS Ratio | 55.41 |
| Forward PS | 4.69 |
| PB Ratio | 25.76 |
| P/TBV Ratio | 30.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 47.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.32 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.96 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -72.31% |
| Return on Assets (ROA) | -24.14% |
| Return on Invested Capital (ROIC) | -97.68% |
| Return on Capital Employed (ROCE) | -44.48% |
| Weighted Average Cost of Capital (WACC) | 10.95% |
| Revenue Per Employee | $160,723 |
| Profits Per Employee | -$649,316 |
| Employee Count | 231 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.40M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +51.90% |
| 50-Day Moving Average | 27.31 |
| 200-Day Moving Average | 25.25 |
| Relative Strength Index (RSI) | 62.46 |
| Average Volume (20 Days) | 1,407,218 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.58M |
| Short Previous Month | 5.29M |
| Short % of Shares Out | 7.86% |
| Short % of Float | 8.47% |
| Short Ratio (days to cover) | 5.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 37.13M |
| Gross Profit | -91.58M |
| Operating Income | -155.56M |
| Pretax Income | -151.39M |
| Net Income | -149.99M |
| EBITDA | -150.65M |
| EBIT | -155.56M |
| Loss Per Share | -$2.01 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 270.70M |
| Total Debt | 16.01M |
| Net Cash | 306.47M |
| Net Cash Per Share | $4.32 |
| Equity (Book Value) | 80.37M |
| Book Value Per Share | 1.13 |
| Working Capital | 251.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -119.34M |
| Capital Expenditures | -1.21M |
| Depreciation & Amortization | 4.91M |
| Net Borrowing | n/a |
| Free Cash Flow | -120.54M |
| FCF Per Share | -$1.70 |
Margins
| Measure | Value |
|---|
| Gross Margin | -246.66% |
| Operating Margin | -418.99% |
| Pretax Margin | -407.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.84% |
| Shareholder Yield | 0.84% |
| Earnings Yield | -6.93% |
| FCF Yield | -5.86% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $41.50 |
| Price Target Difference | 43.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 38.66% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.58 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |